Hemispherx Biopharma (HEB) Files for Treatment Expansion in Argentina for Alferon N Injection® for Hepatitis C  
10/1/2012 9:55:24 AM

PHILADELPHIA, Oct. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced that the Company has filed with ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, an amended NDA for the use of its natural-source Alferon N Injection® (under the brand name "Naturaferon") in patients with chronic hepatitis C who have become refractory to recombinant interferon as a result of the appearance of neutralizing antibodies (NABs) against recombinant interferon. As previously announced, ANMAT has already approved the sale of Naturaferon in Argentina for the treatment of refractory or recurring external condylomata acuminata (genital warts).